Ceftazidime tobramycin fixed drug combination (FDC) versus ceftazidime in lower respiratory tract infections

Completed

• Conditions: ower respiratory tract infections; Infections and Infestations; Lower respiratory tract infections

• Registration Number: ISRCTN69844323
• Lead Sponsor: Venus Remedies Limited (India)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-05-15
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

1. Participants aged greater than 18 years (n = 240), either sex
2. Hopsitalised patients suffering from lower respiratory tract infections

Exclusion Criteria

1. Patients having received antibiotic treatment within two weeks of therapy
2. History of hypersensitivity reaction or any specific contraindication to beta lactams
3. Presence of hepatic or renal disorders
4. Pregnancy or lactation
5. History of hearing loss
6. Alcoholics
7. Previous history seizure

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in clinical and laboratory parameters, measured on day 0 and day 7, followed up to 10 days after the treatment.

Secondary Outcome Measures

Name	Time	Method
To observe incidence of adverse events as assessed by clinical evaluation and laboratory parameters, measured on day 0 and day 7, followed up to 10 days after the treatment.